Miebach, Lisa, Wolfsgruber, Steffen, Polcher, Alexandra, Peters, Oliver, Menne, Felix, Luther, Katja, Incesoy, Enise, Priller, Josef, Spruth, Eike, Altenstein, Slawek, Buerger, Katharina, Catak, Cihan, Janowitz, Daniel, Perneczky, Robert, Utecht, Julia, Laske, Christoph, Buchmann, Martina, Schneider, Anja ORCID: 0000-0001-9540-8700, Fliessbach, Klaus, Kalbhen, Pascal, Heneka, Michael T., Brosseron, Frederic, Spottke, Annika, Roy, Nina, Teipel, Stefan J., Kilimann, Ingo, Wiltfang, Jens ORCID: 0000-0003-1492-5330, Bartels, Claudia, Duezel, Emrah, Dobisch, Laura, Metzger, Coraline, Meiberth, Dix, Ramirez, Alfredo ORCID: 0000-0003-4991-763X, Jessen, Frank and Wagner, Michael ORCID: 0000-0003-2589-6440 (2019). Which features of subjective cognitive decline are related to amyloid pathology? Findings from the DELCODE study. Alzheimers Res. Ther., 11. LONDON: BMC. ISSN 1758-9193

Full text not available from this repository.

Abstract

BackgroundSubjective cognitive decline (SCD) has been proposed as a pre-MCI at-risk condition of Alzheimer's disease (AD). Current research is focusing on a refined assessment of specific SCD features associated with increased risk for AD, as proposed in the SCD-plus criteria. We developed a structured interview (SCD-I) for the assessment of these features and tested their relationship with AD biomarkers.MethodsWe analyzed data of 205 cognitively normal participants of the DELCODE study (mean age=68.9years; 52% female) with available CSF AD biomarkers (A beta-42, p-Tau181, A beta-42/Tau ratio, total Tau). For each of five cognitive domains (including memory, language, attention, planning, others), a study physician asked participants about the following SCD-plus features: the presence of subjective decline, associated worries, onset of SCD, feeling of worse performance than others of the same age group, and informant confirmation. We compared AD biomarkers of subjects endorsing each of these questions with those who did not, controlling for age. SCD was also quantified by two summary scores: the number of fulfilled SCD-plus features, and the number of domains with experienced decline. Covariate-adjusted linear regression analyses were used to test whether these SCD scores predicted abnormality in AD biomarkers.ResultsLower A beta-42 levels were associated with a reported decline in memory and language abilities, and with the following SCD-plus features: onset of subjective decline within 5years, confirmation of cognitive decline by an informant, and decline-related worries. Furthermore, both quantitative SCD scores were associated with lower A beta 42 and lower A beta 42/Tau ratio, but not with total Tau or p-Tau181.ConclusionsFindings support the usefulness of a criterion-based interview approach to assess and quantify SCD in the context of AD and validate the current SCD-plus features as predictors of AD pathology. While some features seem to be more closely associated with AD biomarkers than others, aggregated scores over several SCD-plus features or SCD domains may be the best predictors of AD pathology.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Miebach, LisaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wolfsgruber, SteffenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Polcher, AlexandraUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Peters, OliverUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Menne, FelixUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Luther, KatjaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Incesoy, EniseUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Priller, JosefUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Spruth, EikeUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Altenstein, SlawekUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Buerger, KatharinaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Catak, CihanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Janowitz, DanielUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Perneczky, RobertUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Utecht, JuliaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Laske, ChristophUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Buchmann, MartinaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schneider, AnjaUNSPECIFIEDorcid.org/0000-0001-9540-8700UNSPECIFIED
Fliessbach, KlausUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kalbhen, PascalUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Heneka, Michael T.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Brosseron, FredericUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Spottke, AnnikaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Roy, NinaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Teipel, Stefan J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kilimann, IngoUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wiltfang, JensUNSPECIFIEDorcid.org/0000-0003-1492-5330UNSPECIFIED
Bartels, ClaudiaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Duezel, EmrahUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Dobisch, LauraUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Metzger, CoralineUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Meiberth, DixUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ramirez, AlfredoUNSPECIFIEDorcid.org/0000-0003-4991-763XUNSPECIFIED
Jessen, FrankUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wagner, MichaelUNSPECIFIEDorcid.org/0000-0003-2589-6440UNSPECIFIED
URN: urn:nbn:de:hbz:38-134448
DOI: 10.1186/s13195-019-0515-y
Journal or Publication Title: Alzheimers Res. Ther.
Volume: 11
Date: 2019
Publisher: BMC
Place of Publication: LONDON
ISSN: 1758-9193
Language: English
Faculty: Faculty of Management, Economy and Social Sciences
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
ALZHEIMERS-DISEASE; MEMORY COMPLAINTS; OLDER-ADULTS; DEMENTIA; ASSOCIATION; BIOMARKERS; BETA; IMPAIRMENT; VALIDATION; FRAMEWORKMultiple languages
Clinical Neurology; NeurosciencesMultiple languages
Refereed: Yes
URI: http://kups.ub.uni-koeln.de/id/eprint/13444

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item